Patents by Inventor James Bradford Kline
James Bradford Kline has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230398232Abstract: Tumors utilize multiple mechanisms to avoid the host's anti-tumor immune response. Humoral immunosuppression is one of the mechanisms. Tumors produce circulating factors that can suppress antibody or complement-mediated immune responses to enhance their own survival. Mesothelin is a cell surface protein overexpressed by several cancer types that are associated with tumors exhibiting immunosuppressed microenvironments. Anti-mesothelin antibodies are often subject to such immunosuppressive microenvironments. Alternatively formatted anti-mesothelin antibodies, however, are effective in killing mesothelin-expressing cancers irrespective of tumor microenvironment immune status.Type: ApplicationFiled: September 28, 2021Publication date: December 14, 2023Inventors: Luigi Grasso, Nicholas C. Nicolaides, James Bradford Kline
-
Publication number: 20230203182Abstract: The CA125/MUC16 protein has been found to be a suppressor of humoral immunity, in particular, antibody-mediated humoral immunity mediated through the direct binding to a subset of antibodies. Antibody variants can be generated that have reduced or eliminated CA125 binding yet retain the antigen specificity of the parental antibody. These can be used in treating patients with elevated CA125. CA 125-refractory antibodies are developed and used for treatment. Additionally, proteins that enhance humoral immunity in the presence of CA125 can be used to counter the suppression of humoral immunity.Type: ApplicationFiled: December 29, 2020Publication date: June 29, 2023Inventors: Nicholas C. Nicolaides, Luigi Grasso, James Bradford Kline
-
Publication number: 20230001004Abstract: Provided herein are methods for generating conjugated immunoglobulins, the method comprising: decapping a cysteine at amino acid position 80 (“Cys80”) in a light chain variable region of an immunoglobulin, wherein the immunoglobulin comprises a heavy chain variable region and the light chain variable region; and conjugating a thiol-reactive compound to the Cys80, wherein the thiol-reactive compound comprises a thiol-reactive group. Antigen-binding molecules and methods for generating the same, immunoglobulins as well as nucleic acid molecules encoding the immunoglobulins and host cells comprising the nucleic acid molecules, conjugated immunoglobulins, and light chain variable regions for use in a conjugated immunoglobulin are also provided.Type: ApplicationFiled: September 2, 2021Publication date: January 5, 2023Inventors: Luigi Grasso, Jared Spidel, James Bradford Kline, Earl Albone
-
Patent number: 11129904Abstract: Provided herein are methods for generating conjugated immunoglobulins, the method comprising: decapping a cysteine at amino acid position 80 (“Cys80”) in a light chain variable region of an immunoglobulin, wherein the immunoglobulin comprises a heavy chain variable region and the light chain variable region; and conjugating a thiol-reactive compound to the Cys80, wherein the thiol-reactive compound comprises a thiol-reactive group. Antigen-binding molecules and methods for generating the same, immunoglobulins as well as nucleic acid molecules encoding the immunoglobulins and host cells comprising the nucleic acid molecules, conjugated immunoglobulins, and light chain variable regions for use in a conjugated immunoglobulin are also provided.Type: GrantFiled: March 14, 2019Date of Patent: September 28, 2021Assignee: Eisai R&D Managment Co., Ltd.Inventors: Luigi Grasso, Jared Spidel, James Bradford Kline, Earl Albone
-
Publication number: 20210040174Abstract: The CA125/MUC16 protein has been found to be a suppressor of humoral immunity, in particularly antibody-mediated humoral immunity. The generation of antagonists that can block its immune suppressive effects on antibodies may lead to enhanced therapeutic responses by antibodies that are negatively impacted by CA125/MUC16. In addition, it offers the ability to unlock humoral immune suppression of a patient's endogenous humoral response that may be suppressed by CA125/MUC16 suppression. CA125/MUC16 antagonists can be used to enhance humoral response of therapeutic antibodies and patients with CA125/MUC16-expressing diseases, including cancer.Type: ApplicationFiled: August 4, 2020Publication date: February 11, 2021Applicant: Navrogen, Inc.Inventors: Nicholas C. Nicolaides, Luigi Grasso, James Bradford Kline
-
Publication number: 20190202933Abstract: Provided herein are methods for generating conjugated immunoglobulins, the method comprising: decapping a cysteine at amino acid position 80 (“Cys80”) in a light chain variable region of an immunoglobulin, wherein the immunoglobulin comprises a heavy chain variable region and the light chain variable region; and conjugating a thiol-reactive compound to the Cys80, wherein the thiol-reactive compound comprises a thiol-reactive group. Antigen-binding molecules and methods for generating the same, immunoglobulins as well as nucleic acid molecules encoding the immunoglobulins and host cells comprising the nucleic acid molecules, conjugated immunoglobulins, and light chain variable regions for use in a conjugated immunoglobulin are also provided.Type: ApplicationFiled: March 14, 2019Publication date: July 4, 2019Inventors: Luigi Grasso, Jared Spidel, James Bradford Kline, Earl Albone
-
Patent number: 10273310Abstract: Provided herein are methods for generating conjugated immunoglobulins, the method comprising: decapping a cysteine at amino acid position 80 (“Cys80”) in a light chain variable region of an immunoglobulin, wherein the immunoglobulin comprises a heavy chain variable region and the light chain variable region; and conjugating a thiol-reactive compound to the Cys80, wherein the thiol-reactive compound comprises a thiol-reactive group. Antigen-binding molecules and methods for generating the same, immunoglobulins as well as nucleic acid molecules encoding the immunoglobulins and host cells comprising the nucleic acid molecules, conjugated immunoglobulins, and light chain variable regions for use in a conjugated immunoglobulin are also provided.Type: GrantFiled: June 17, 2016Date of Patent: April 30, 2019Assignee: Eisai R&D Management Co., Ltd.Inventors: Luigi Grasso, Jared Spidel, James Bradford Kline, Earl Albone
-
Patent number: 9809647Abstract: The present invention relates to novel humanized, chimeric and murine antibodies that have binding specificity for the human CC chemokine ligand 20 (CCL20). The present invention further relates to heavy chains and light chains of said antibodies. The invention also relates to isolated nucleic acids, recombinant vectors and host cells that comprise a sequence which encodes a heavy chain and/or a light chain of said antibodies, and to a method of preparing said antibodies. The anti-CCL20 antibodies of the invention can be used in therapeutic applications to treat, for example, inflammatory and autoimmune disorders and cancer.Type: GrantFiled: August 3, 2015Date of Patent: November 7, 2017Assignee: Eisai R&D Management Co., Ltd.Inventors: Toshio Imai, James Bradford Kline, Tetsu Kawano, Luigi Grasso, Yoshimasa Sakamoto, Jared Spidel, Miyuki Nishimura, Kenzo Muramoto, Tatsuo Horizoe
-
Publication number: 20160369011Abstract: Provided herein are methods for generating conjugated immunoglobulins, the method comprising: decapping a cysteine at amino acid position 80 (“Cys80”) in a light chain variable region of an immunoglobulin, wherein the immunoglobulin comprises a heavy chain variable region and the light chain variable region; and conjugating a thiol-reactive compound to the Cys80, wherein the thiol-reactive compound comprises a thiol-reactive group. Antigen-binding molecules and methods for generating the same, immunoglobulins as well as nucleic acid molecules encoding the immunoglobulins and host cells comprising the nucleic acid molecules, conjugated immunoglobulins, and light chain variable regions for use in a conjugated immunoglobulin are also provided.Type: ApplicationFiled: June 17, 2016Publication date: December 22, 2016Inventors: Luigi Grasso, Jared Spidel, James Bradford Kline, Earl Albone
-
Publication number: 20160046707Abstract: The present invention relates to novel humanized, chimeric and murine antibodies that have binding specificity for the human CC chemokine ligand 20 (CCL20). The present invention further relates to heavy chains and light chains of said antibodies. The invention also relates to isolated nucleic acids, recombinant vectors and host cells that comprise a sequence which encodes a heavy chain and/or a light chain of said antibodies, and to a method of preparing said antibodies. The anti-CCL20 antibodies of the invention can be used in therapeutic applications to treat, for example, inflammatory and autoimmune disorders and cancer.Type: ApplicationFiled: August 3, 2015Publication date: February 18, 2016Inventors: Toshio Imai, James Bradford Kline, Tetsu Kawano, Luigi Grasso, Yoshimasa Sakamoto, Jared Spidel, Miyuki Nishimura, Kenzo Muramoto, Tatsuo Horizoe
-
Patent number: 9133273Abstract: The present invention relates to novel humanized, chimeric and murine antibodies that have binding specificity for the human CC chemokine ligand 20 (CCL20). The present invention further relates to heavy chains and light chains of said antibodies. The invention also relates to isolated nucleic acids, recombinant vectors and host cells that comprise a sequence which encodes a heavy chain and/or a light chain of said antibodies, and to a method of preparing said antibodies. The anti-CCL20 antibodies of the invention can be used in therapeutic applications to treat, for example, inflammatory and autoimmune disorders and cancer.Type: GrantFiled: June 21, 2013Date of Patent: September 15, 2015Assignee: Eisai R&D Management Co., Ltd.Inventors: Toshio Imai, James Bradford Kline, Tetsu Kawano, Luigi Grasso, Yoshimasa Sakamoto, Jared Spidel, Miyuki Nishimura, Kenzo Muramoto, Tatsuo Horizoe